FdaApplication
NDA 208464
Identifiers
- fda_app_no: NDA208464
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2016-11-10 |
Revenue by product
VEMLIDY
| Period | Revenue |
|---|---|
| Q2 2026 | $289.0M |
| Q1 2026 | $237.0M |
| Q4 2025 | $287.0M |
| Q3 2025 | $280.0M |
| Q2 2025 | $252.0M |
| Q1 2025 | $252.0M |
| Q4 2024 | $260.0M |
| Q3 2024 | $232.0M |
| Q2 2024 | $243.0M |
| Q1 2024 | $225.0M |
| Q4 2023 | $434.0M |
| Q3 2023 | $456.0M |
| Q2 2023 | $219.0M |
| Q1 2023 | $199.0M |
| Q4 2022 | $220.0M |
| Q3 2022 | $228.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VEMLIDY | TENOFOVIR ALAFENAMIDE FUMARATE | EQ 25MG BASE | TABLET;ORAL |
1 product